The state of Missouri currently has 3 active clinical trials seeking participants for Primary Biliary Cholangitis research studies. These trials are conducted in various cities, including Saint Louis, Kansas City, St. Louis and Springfield.
IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Recruiting
To Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/08/2024
Locations: Kansas City Research Institute, Kansas City, Missouri
Conditions: Primary Biliary Cholangitis
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Recruiting
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects with Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
01/26/2024
Locations: Southern Therapy and Advanced Research, Jackson, Missouri
Conditions: Primary Biliary Cholangitis, Compensated Cirrhosis, Hepatic Impairment
Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis
Recruiting
Saroglitazar Magnesium 1 mg and 2 mg tablets for treatment of subjects with Primary Biliary Cholangitis (PBC)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/30/2023
Locations: Zydus US030, Saint Louis, Missouri
Conditions: Primary Biliary Cholangitis